EISAI CO (ESALY)

55.85
3.25 6.19
OTC
Prev Close 52.60
Open 55.75
Day Low/High 54.35 / 56.25
52 Wk Low/High 52.26 / 101.80
Volume 74.12K
Exchange OTC
Shares Outstanding 296.57B
Market Cap 25.06B
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's Thoughts on Micron, Biogen, Apple and Tesla

Jim Cramer's Thoughts on Micron, Biogen, Apple and Tesla

Jim Cramer weighs in on Micron's earnings, Biogen's fall, Apple's upcoming event and Elon Musk.

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.

Jim Cramer Breaks Down Micron, Biogen and Apple

Jim Cramer Breaks Down Micron, Biogen and Apple

Jim Cramer has his eyes on Micron's earnings, Biogen's disappointment and Apple's upcoming event.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Biogen Shares Plummet Despite Alzheimer's Drug Exceeding Expectations

Biogen Shares Plummet Despite Alzheimer's Drug Exceeding Expectations

Shares fell by more than 11% in after hours trading Wednesday.

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

3 Things to Watch When Biogen Reports Second-Quarter Results

3 Things to Watch When Biogen Reports Second-Quarter Results

The Cambridge, Mass.-based biotech is scheduled to unveil its second-quarter results before the market open on July 24.

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Here's what you need to know now for Friday, July 6.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

Biogen Wins a Battle, Not the War Against Alzheimer's

Biogen Wins a Battle, Not the War Against Alzheimer's

The history of trying to cure Alzheimer's is full of mistakes and false promises.

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks.

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Ever Wondered About the Japanese FANGs? Here They Are

Ever Wondered About the Japanese FANGs? Here They Are

The days of rapid growth are far behind Japan. So can these Tokyo listings deliver as much bite as the FANGs?

These Stocks Could Be the Japanese FANGs

These Stocks Could Be the Japanese FANGs

The days of rapid growth are far behind Japan. So can these Tokyo listings deliver as much bite as the FANGs?

A Very Happy New Year for Investors in Japan

A Very Happy New Year for Investors in Japan

The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.